Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies-Reference-Cited by-同舟云学术

Controversies in off‐label prescriptions in dermatology: the perspective of the patient, the physician, and the pharmaceutical companies

Published:2018-08-31 Issue:7 Volume:58 Page:788-794
ISSN:0011-9059
Container-title:International Journal of Dermatology
language:en
Short-container-title:Int J Dermatol

Author:

França Katlein¹^ORCID,Litewka Sergio¹

Affiliation:

1. Department of Dermatology & Cutaneous Surgery Institute for Bioethics & Health Policy University of Miami Miller School of Medicine Miami FL USA

Publisher

Wiley

Subject

Dermatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ijd.14222

Reference46 articles.

1. Off-label use of medicine: Perspective of physicians, patients, pharmaceutical companies and regulatory authorities

2. How Drugs are Developed and Approved by the FDA: Current Process and Future Directions

3. FDA.About the Center for Drug Evaluation and Research.2018.https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/default.htm.

4. FDA.Development & Approval Process (Drugs).2018.https://www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm.

5. Ten Common Questions (and Their Answers) About Off-label Drug Use

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Off-label medications in the treatment of hospitalized children with atopic dermatitis;Advances in Dermatology and Allergology;2023

2. On which evidence can we rely when prescribing off-label methotrexate in dermatological practice? – a systematic review with GRADE approach;Journal of Dermatological Treatment;2021-08-23

3. Comparing prescribing patterns for topical corticosteroids based on their FDA indication by age;Pediatric Dermatology;2020-11-10

4. Prescriptions hors AMM (autorisation de mise sur le marché) dans le psoriasis de l’enfant;Annales de Dermatologie et de Vénéréologie;2020-06

5. Current regulatory approaches for accessing potential COVID-19 therapies;Journal of Pharmaceutical Policy and Practice;2020-05-16